ESMO 2017: Combined lenvatinib and everolimus produces notable response rates in advcanced renal carcinoma

Interim results were announced today from the advanced renal cell carcinoma (RCC) cohort of Study 111, a Phase 1b/2 study investigating lenvatinib, a multiple receptor tyrosine kinase inhibitor (including fibroblast growth factor receptors, in combination...

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2wSzLDi
via IFTTT